Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic TM Antisense ...

Sanofi has entered into a collaboration and license agreement with Alloy Therapeutics to develop an antisense oligonucleotide (ASO) therapy targeting a single, undisclosed central nervous system ...

Sanofi has tapped Alloy Therapeutics to enable development of a central nervous system drug, agreeing to pay $27.5 million in upfront and near-term fees to access an antisense platform.

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5m.

Morningstar brands and products Company Portfolio ...

In return, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5 million. Alloy will also be eligible to receive discovery, development ...

Privately-held US biotech Alloy Therapeutics has announced a target specific collaboration and license agreement for the use of its novel and proprietary anticlastic antisense platform with French ...